. Methylprednisolone Combined with Azithromycin on Serum Biochemical Factors (CRP, PCT, IL-6, TNF-α )
Running title: Serum Biochemical Factors (CRP, PCT, IL-6, TNF-α )
Abstract
Introduction: it was to demonstrate effects of methylprednisolone (MPS) and azithromycin treatment on serum biochemical factors and their impact on Serum Biochemical Factors (CRP, PCT, IL-6, TNF-α ) prognosis in patients with viral pneumonia (VP). Methods: 120 patients with VP admitted to our hospital were rolled into control (Ctrl), low-dose (80 mg MPS, L-MPS), medium-dose (500 mg MPS, M-MPS), and high-dose (1000 mg MPS, H-MPS) groups. The therapeutic efficacy of each group was evaluated. C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) were detected. Pulmonary function parameters were assessed using a pulmonary function testing device. Adverse reactions (ARs) such as fever, nausea, vomiting, and gastrointestinal bleeding post-treatment were recorded.
Results: total effective rate (TER) post-treatment in Ctrl group was 60.00%, which was inferior to that in L-MPS group (76.67%), M-MPS group (90.00%), and H-MPS group (93.33%) (P<0.05). Disappearance time of CRP, PCT, IL-6, TNF-α, fever, cough, and X-ray infiltrates was reduced in L-MPS, M-MPS, and H-MPS groups relative to Ctrl group (P<0.05), while FVC, MMEF, and PEF were increased (P<0.05). Disappearance time of CRP, PCT, IL-6, TNF-α, fever, cough, and X-ray infiltrates in M-MPS and H-MPS groups was inferior to that in L-MPS group (P<0.05), while FVC, MMEF, and PEF were higher (P<0.05).
Conclusion: medium-dose (500 mg) MPS combined with azithromycin greatly reduces inflammatory cytokine levels, shortens the time to clinical symptom relief, improves lung function and respiratory capacity, demonstrating significant efficacy in treating VP.
References
1. Febbo J, Revels J, Ketai L. Viral pneumonias. Radiologic Clinics of North America, 2022;60(3):383-397.
2. Wolfram F, Braun C, Gutsche H, Lesser TG. In vivo assessment of lung ultrasound features mimicking viral pneumonia using a large animal model. IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control, 2020;67(11):2258-2264.
3. Watkins RR. Using precision medicine for the diagnosis and treatment of viral pneumonia. Advances in Therapy, 2022;39(7):3061-3071.
4. Jensen A, Stensballe LG. Viral pneumonia in Danish children. Danish Medical Journal, 2021;68(8):A11200858(1-7).
5. Shang L, Xu J, Cao B. Viral pneumonia in China: from surveillance to response. The Lancet Public Health, 2020;5(12):e633-e634.
6. Goldberg R, Ye W, Johns K, Mucksavage JJ, Dhandapani S, Quigley JG, Shapiro NL, Benken ST, Wenzler E, Kim KS. Comparison of thrombotic and clinical outcomes in SARS-CoV-2-pneumonia versus other viral pneumonia in an urban academic medical center. Heart & Lung, 2023;61:153-157.
7. Cavallazzi R, Ramirez JA. Influenza and viral pneumonia. Infectious Disease Clinics of North America, 2024;38(1):183-212.
8. Firth A, Prathapan P. Azithromycin: the first broad-spectrum therapeutic. European Journal of Medicinal Chemistry, 2020;207:112739(1-10).
9. Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, TESTING Study Group. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA: the Journal of the American Medical Association, 2022;327(19):1888-1898.
10. Meduri GU, Shih MC, Bridges L, Martin TJ, El-Solh A, Seam N, Davis-Karim A, Umberger R, Anzueto A, Sriram P, Lan C, Restrepo MI, Guardiola JJ, Buck T, Johnson DP, Suffredini A, Bell WA, Lin J, Zhao L, Uyeda L, Nielsen L, Huang GD, ESCAPe Study Group. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Medicine, 2022;48(8):1009-1023.
11. Liu Z, Yang Y, He L, Pang M, Luo C, Liu B, Rong L. High-dose methylprednisolone for acute traumatic spinal cord injury: A meta-analysis. Neurology, 2019;93(9):e841-e850.
12. Klompas M, Imrey PB, Yu PC, Rhee C, Deshpande A, Haessler S, Zilberberg MD, Rothberg MB. Respiratory viral testing and antibacterial treatment in patients hospitalized with community-acquired pneumonia. Infection Control and Hospital Epidemiology, 2021;42(7):817-825.
13. Malla D, Rathi V, Gomber S, Upreti L. Can lung ultrasound differentiate between bacterial and viral pneumonia in children?. Journal of Clinical Ultrasound, 2021;49(2):91-100.
14. Fang L, Pei J, Mao S, Wu L, Jiang S. Traditional chinese medicine injection for the treatment of viral pneumonia in children: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 2021;100(16):e25506(1-5).
15. Dubert M, Le Toriellec E, Croisille L, Thomas L, Ducreux M, Froissart A, Herbrecht R, Lebrun-Vignes B, Marolleau JP, Méric JB, Mahevas M, Michel M, Bierling P. Methylprednisolone-induced immune thrombocytopenia. American Journal of Hematology, 2020;95(1):E13-E16.
16. Wang-Liang C, Reid S, Barkley J, Jain P. Methylprednisolone-induced acute pancreatitis, a case presentation. Discovery Medicine, 2022;34(172):79-81.
17. Welzel T, Atkinson A, Schöbi N, Andre MC, Bailey DGN, Blanchard-Rohner G, Buettcher M, Grazioli S, Koehler H, Perez MH, Trück J, Vanoni F, Zimmermann P, Sanchez C, Bielicki JA, Schlapbach LJ, Swissped RECOVERY Trial Group. Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial. The Lancet Child & Adolescent Health, 2023;7(4):238-248.
18. Townsley MM. Methylprednisolone for cardiac surgery in infants: findings from a large-scale, randomized, controlled trial. Journal of Cardiothoracic Vascular Anesthesia, 2023;37(6):860-862.
19. Roddy MR, Sellers AR, Darville KK, Teppa-Sanchez B, McKinley SD, Martin M, Goldenberg NA, Nakagawa TA, Sochet AA. Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial. Pediatric Pulmonology, 2023;58(6):1719-1727.
20. Pfeuffer S, Rolfes L, Wirth T, Steffen F, Pawlitzki M, Schulte-Mecklenbeck A, Gross CC, Brand M, Bittner S, Ruck T, Klotz L, Wiendl H, Meuth SG. Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses. Journal of Neuroinflammation, 2022;19(1):220(1-18).
21. Sámano C, Nistri A. Mechanism of neuroprotection against experimental spinal cord injury by riluzole or methylprednisolone. Neurochem Research, 2019;44(1):200-213.
22. Ma J, Li L, Qie X, Zhao Q, Zhang L, Xu N, Li X, Guo H, Li H, Lv J, Li J. Value of combined detection of PCT, CRP, and FIB in differentiating viral infection from bacterial infection in severe pneumonia. Clinical Laboratory, 2023;69(11):2247-2253.
23. Sun Y, Li J, Nan A, Li Z, Zhong W, Chen L, Liu S, Zhang B, Zhu Z, Li X. Methylprednisolone alleviates cognitive functions through the regulation of neuroinflammation in Alzheimer's disease. Frontiers in Immunology, 2023;14:1192940(1-8).
24. Obling LER, Beske RP, Meyer MAS, Grand J, Wiberg S, Nyholm B, Josiassen J, Søndergaard FT, Mohr T, Damm-Hejmdal A, Bjerre M, Frikke-Schmidt R, Folke F, Møller JE, Kjaergaard J, Hassager C. Prehospital high-dose methylprednisolone in resuscitated out-of-hospital cardiac arrest patients (STEROHCA): a randomized clinical trial. Intensive Care Medicine, 2023;49(12):1467-1478.
25. Subramanian P, Arumugam M, Vaithianathan R. Role of methylprednisolone in the prevention of seroma formation after mastectomy: a randomized controlled trial. Indian Journal of Cancer, 2023;60(2):206-210.
26. Chen X, Li M, Zheng R, Huang Q, Li Y, Zhu Y, Chen Z, Lin J. Effects of sevoflurane inhalation anesthesia on IL-6, TNF-α and MMP-9 expression and hemodynamics in elderly patients undergoing lobectomy for lung cancer. Cellular and Molecular Biology (Noisy-le-Grand, France), 2020;66(5):49-53.
27. Taher Al Barzin RMG, Ghafour Raheem S, Khudhur PK, Abdulkarimi R, Mohammadnejad E, Tabatabaee A. Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length. Cellular and Molecualr Biology (Noisy-le-Grand), 2020;66(6):15-18.
28. He F, Yang R, Li XY, Ye C, He BC, Lin T, Xu XQ, Zheng LL, Luo WT, Cai L. Single nucleotide polymorphisms of the NF-κB and STAT3 signaling pathway genes predict lung cancer prognosis in a Chinese Han population. Cancer Genetics, 2015;208(6):310-318.
29. Karhu J, Ala-Kokko TI, Vuorinen T, Ohtonen P, Julkunen I, Syrjälä HT. Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients. Cytokine, 2019;113:272-276.
Copyright (c) 2025 Xin Chen
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.